Precision BioSciences Surges on Hepatitis B Gene Editing Data
Precision BioSciences stock surged more than 10% in Wednesday premarket trading after Benzinga reported that the company released encouraging new biopsy results from its PBGENE-HBV gene editing program.
Clinical Data Drives the Move
Shares of Precision BioSciences (NASDAQ: DTIL) were indicated at $8.38 ahead of the open, up roughly 10.55% on the session. The catalyst was fresh data showing its PBGENE-HBV therapy can effectively eliminate cccDNA, a persistent form of hepatitis B virus DNA that lodges inside liver cell nuclei and resists conventional antiviral treatment.
The biopsy results showed a tenfold reduction in transcripts derived from cccDNA. Every patient who had detectable pgRNA at the start of the study achieved complete pgRNA loss by the measured endpoint. That readout is clinically meaningful because pgRNA serves as a replication template for the virus. Eliminating it signals a potential path toward functional cure of chronic hepatitis B, a disease affecting an estimated 250 million people worldwide.
Why cccDNA Matters in Hepatitis B
Chronic hepatitis B remains notoriously difficult to treat because existing nucleoside analogue therapies suppress viral replication but cannot clear cccDNA from infected cells. Once treatment stops, the virus typically rebounds. Gene editing approaches that physically destroy the cccDNA reservoir represent a fundamentally different strategy. Precision BioSciences uses its proprietary ARCUS nuclease platform, which the company describes as a fully human-derived genome editing system designed for high specificity.
Where the Stock Stands Technically
Prior to Wednesday’s move, DTIL had already climbed more than 55% over the trailing twelve months. The stock was trading well above its key moving averages heading into the session. Its 20-day simple moving average sat near $7.45, while the 50-day average was around $7.00. The 52-week high of $8.82 represents the next meaningful resistance level if momentum holds through the regular session.
Analyst Outlook and Next Catalysts
Wall Street remains constructive on the name. Jones Trading carries a Buy rating with a price target of $30.00, issued in April. The next formal financial update is expected around August 6, where analysts project a per-share loss of 58 cents on revenue near $2.06 million. Both figures represent a significant improvement over the year-ago period, reflecting reduced cash burn and early commercial progress.
Investors will be watching for further clinical updates from the PBGENE-HBV program as the company advances toward later-stage trial design.
Read Next: What Is Gene Editing and Why Does It Matter for Biotech Investors?
